IN8bio (NASDAQ:INAB) Posts Quarterly Earnings Results

IN8bio (NASDAQ:INAB) issued its earnings results on Thursday. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.10, FiscalAI reports.

IN8bio Price Performance

Shares of IN8bio stock traded up $0.10 during trading hours on Friday, reaching $0.93. The company had a trading volume of 33,376 shares, compared to its average volume of 39,109. IN8bio has a one year low of $0.80 and a one year high of $2.73. The business has a fifty day simple moving average of $1.13 and a 200 day simple moving average of $1.42.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of IN8bio in a report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold”.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.